The sell-off from 2PM onwards was pretty dang ugly. I think it's mostly the buyers early on getting scared and juming out with big losses. From social media on stocktwits and the few losers posting nonsense on this MB, looks like few understand that this trial was not a complete failure. Can't really get a read on sentiment from a few drunken stooges though...
I'll bet you $65,000 that it's not going BK, with 85.5M in the bank as of the last ER, a viable product for 80% of patients, and a 30M cash burn.
Read the 8-K!
It does work. The trial was a comparison with timolol. It failed the primary endpoint for patients with IOPs of 26mmHg or more, but was equal at 25, and surpassed at 24.
It will be approved and sold for majority of patients with an IOP of 24 or less, and I think it could be potentially used in combination with the other patients once they have used timolol for a bit.
"Based on further analysis, RhopressaTM demonstrated non-inferiority compared to timolol for patients in the study with IOPs below 26mmHg at all nine measured time points and numerical superiority over timolol at the majority of measured time points. The Baltimore Eye Survey points to approximately 80 percent of newly diagnosed glaucoma patients having IOPs of 26mmHg or less. In addition, RhopressaTM demonstrated, in a pre-specified analysis, non-inferiority to timolol and numerical superiority over timolol at all nine measured time points for patients in the study with IOPs below 24mmHg. We also noted that the number of RhopressaTM patients that experienced loss of efficacy over time was reduced to half for patients with IOPs less than 26mmHg, and the frequency of such occurrence progressively decreased for RhopressaTM patients with lower IOPs."
LOL! You didn't spell it right, yet again.
In the last report, they had 85,586 in cash and their R&D costs were 30M last year.
Who is paying you to spew FUD?
'Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company is conducting a Phase 3 registration trial in the United States, named “Rocket 2,” where the primary efficacy endpoint will be to demonstrate non-inferiority of IOP lowering for RhopressaTM compared to timolol, along with a Phase 3 registration safety-only trial, named “Rocket 3,” in Canada. The Company recently completed its initial Phase 3 registration trial, “Rocket 1,” the three-month efficacy results of which are reported in this press release. The Company also completed a Phase 2b clinical trial in which RoclatanTM met the primary efficacy endpoint, demonstrating the statistical superiority of RoclatanTM to each of its components.'
It's not in the same "industry" as a "momentum" stock. All the 3D printer stocks are crashing.
Well, looks like Best Buy made a half-hearted effort there, maybe for some up-front cash. The public is dumber than a bag of rocks, and 3D systems is trying to cash in on the Apple "fanboys" with The Cube's design and marketing -- but of course, none of this is as easy as it looks.
It took about half a century of GUI design and miniaturization improvements before most people understood how to use a computer. I would not expect the general public to have a 3D printer in their hands, ever. Maybe 10%? 15%? That would be a huge growth from where it is now.
It makes sense. Anything related to industrial manufacturing gets hit. That industrial manufacturing (in the US and Europe) has a lot to do with supplying equipment and other material for energy companies.
Oil cost reductions benefit direct consumers more -- that's car owners, ticket buyers, food buyers, and light manufacturing consumers (e.g. clothing) -- all of these depend a lot on transport costs, which go down in price if oil goes down in price.
In terms of the consumer space, 3D Systems is actually reporting they did better than they expected, which is a bit surprising for me.
The cheapest 3D printer is currently $179, minus shipping. (called Tiko -- I ordered 2) A lot of modeling software is free. Scanning capture hardware is not, though, but I don't think it's essential. There's also the cost of a plastic recycler to reduce the supply cost (filament is expensive). I pre-ordered the Protocycler for that, and that is $700.
Tiko doesn't have a big volume, but I think that we are pretty close to big volume printers costing $400-$500, and most people wouldn't even need a big volume anyway.
Oil prices have stabilized, and so have currency swings. No momo for DDD, and back down I guess, but there is a silver lining in the report:
"Specifically, OEMs that paused to assess their own exposure to foreign currency and macroeconomic impacts are beginning to resume their capital investments and are making the purchases they deferred during the first quarter." (Reichental)
I don't believe this is PR spin.
Amazon is now seen as more than an online book store, so now their market cap jumps 15%. It's not just about technology.